GMDP for psoriasis

Lancet

Volumn 352, Issue 9127, 1998, Pages 545-

  Williamson, D ^a   Chawla, M ^a   Marks, R ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MURAMYL DIPEPTIDE DERIVATIVE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSORIASIS; SIDE EFFECT;

EID: 0032529345     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)79253-9     Document Type: Article

References (5)

1. 1 Ellouz F, Adams A, Ciorbaru, Lederer D. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res 1974; 59: 1317-25.
2. 2 Andronova T, Ivonova V. The structure and immunomodulating function of glucosaminylmuramyl peptides. Sov Med Rev D Immunol 1991; 4: 1-63.
3. 3 Dinarella CA, Elin RJ, Chedid L, Wolff SM. The pyrogenicity of the synthetic adjuvant muramyl dipeptide and two structural analogues. J Infect Dis 1978; 138: 760-67.
4. 4 Chedid L, Parant M, Parant F, Lefrancier P, Choay J, Lederer E. Enhancement of non specific immunity to Klebsiella pneumoniae infection by a synthetic adjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine) and several analogues. Proc Natl Acad Sci 1977; 74: 2089.
5. 5 Zidek Z, Capkova J, Boubelik M, Masek K. Opposite effects of the synthetic immunomodulator muramyl dipeptide on the rejection of mouse skin allografts. Eur J Immunol 1983; 13: 859.